Pharmather Reports Improved Q3 Results, Continues Ketamine Trials For Epilepsy

Pharmather Holdings Ltd. (OTCQB: PHRRF) reported financial results for its third quarter ended February 28, 2022.

Financial Results

Cash and cash equivalents totaled CA$10,165,170 ($7,955,803) and investment totaled CA$1,666,667 ($1,304,422) for a total of CA$11,831,837 ($9,260,226) as of February 28, 2022.

Accounts payable and accrued liabilities totaled CA$140,947 ($110,312) as of February 28, 2022.

Recent Highlights

The company received an Orphan Drug Designation for a ketamine-based medicine for treating an epileptic condition.

Received approval from the FDA to proceed with a Phase 2 clinical trial for an Amyotrophic Lateral Sclerosis treatment.

The company entered into collaborative research with Revive Therapeutics (OTCQB: RVVTF) to develop a psilocybin microneedle patch. Pharmather is also developing microneedle patches for administering ketamine (along with LTS Lohmann Therapie-Systeme AG) and another one for administering LSD.

Photo by micheile on Unsplash

Market News and Data brought to you by Benzinga APIs
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: BiotechCannabisEarningsNewsPsychedelicsMarketsGeneralPharmaTher Holdings Ltd.Revive Therapeutics
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

The Benzinga Cannabis Capital Conference is coming to Florida

The Benzinga Cannabis Capital Conference is returning to Florida, in a new venue in Hollywood, on April 16 and 17, 2024. The two-day event at The Diplomat Beach Resort will be a chance for entrepreneurs, both large and small, to network, learn and grow. Renowned for its trendsetting abilities and influence on the future of cannabis, mark your calendars – this conference is the go-to event of the year for the cannabis world.

Get your tickets now on – Prices will increase very soon!